Sun Life and Wilton Re announce a strategic partnership, combining depth and breadth of capabilities across life and annuity reinsurance and asset management

Sun Life (SLF) Q2 2026 earnings call transcript says insurance sales rose 20% to CAD 875 million, with growth across Asia and the U.S. Asset management net flows and net wealth sales improved by CAD 16.3 billion. Underlying EPS grew 13% and underlying ROE was 19.1%. The firm renewed a normal course issuer bid to repurchase up to 10 million shares.

FTSE 100 was down about 30 points near 10,801 as miners fell after Antofagasta cut 2026 copper output guidance to 625,000-655,000 tonnes. JPMorgan upgraded Aviva to overweight and downgraded Legal & General and M&G. UK Q2 GDP grew 0.4%. Investors awaited US producer prices and jobless claims; US inflation eased to 3.4% in July.

Sun Life Financial (NYSE:SLF) reported Q2 results and shareholder returns. The company said it returned about CAD 500 million via common dividends (3.8% yield) and renewed a normal course issuer bid for up to 10 million shares, buying 0.8 million as of the call. Underlying net income rose across segments, with asset management underlying net income at CAD 262 million (+4%).

Sun Life Financial reported Q2 2026 underlying earnings of $1.46 per share, above the Zacks estimate of $1.39. Underlying net income rose 11% to C$1.12 billion, with revenues up to $10.09 billion. Insurance sales grew, assets under management rose to C$1.70 trillion, and the LICAT ratio was 145%.

Sun Life Financial reported Q2 group insurance sales of CA$680 million, up 27% year over year, and individual insurance sales of CA$1.002 billion, up 16%. US sales rose 43% to US$324 million, helped by medical stop-loss. Underlying net income was CA$1.123 billion. Sun Life also said it connected to Centro’s platform via an API to automate RFP quoting.

Sun Life Financial reported Q2 profit of $1.0 billion, up 41% from $716 million a year earlier, and EPS of $1.81 versus $1.26. The Toronto insurer attributed part of the gain to favourable public equity market impacts. Underlying EPS rose to $2.02 from $1.79, with momentum in health and individual protection, according to the company.